Edgewise Therapeutics, Inc. (EWTX) Revenue History
Annual and quarterly revenue from 2019 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
EWTX Revenue Growth
EWTX Revenue Analysis (2019–2025)
As of May 8, 2026, Edgewise Therapeutics, Inc. (EWTX) generated trailing twelve-month (TTM) revenue of $0. The most recent quarter (Q1 2026) recorded $0 in revenue.
Looking at the longer-term picture, EWTX's historical revenue data shows various trends over time.
When compared to Healthcare sector peers including ACAD (+9.9% YoY), KYMR (-12.6% YoY), and ARQT (+95.3% YoY). Compare EWTX vs ACAD →
EWTX Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| EWTXCurrent | $0 | - | - | - | |
 ACAD | $1.1B | +9.9% | +19.4% | 9.8% | |
 KYMR | $39M | -12.6% | +2.9% | -891.3% | |
 ARQT | $376M | +95.3% | - | -3.3% |
EWTX Historical Revenue Data (2019–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $0 | - | $-2,266,000 | - | $-191,406,000 | - |
| 2024 | $0 | - | $0 | - | $-158,832,000 | - |
| 2023 | $0 | - | $0 | - | $-114,357,000 | - |
| 2022 | $0 | - | $0 | - | $-71,658,000 | - |
| 2021 | $0 | - | $0 | - | $-43,215,000 | - |
| 2020 | $0 | - | $-185,000 | - | $-17,192,000 | - |
| 2019 | $0 | - | $-123,000 | - | $-9,924,000 | - |
See EWTX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs EWTX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare EWTX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonEWTX — Frequently Asked Questions
Quick answers to the most common questions about buying EWTX stock.
Is EWTX's revenue growth accelerating or slowing?
EWTX TTM revenue: $0.00. YoY growth: N/A. 5-year CAGR: N/A.
What is EWTX's long-term revenue growth rate?
Edgewise Therapeutics, Inc.'s 5-year revenue CAGR of N/A reflects the variable expansion pattern. Current YoY growth of N/A is near this long-term average.
How is EWTX's revenue distributed by segment?
EWTX reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2019-2025 are available for download. Segment mix reveals concentration and diversification trends.